Medical Center

Primary Total: $52,502,661


College of Medicine

Total: $42,538,086

Primary Total: $39,077,134


Neurosurgery

Total: $2,555,687

Primary Total: $2,250,228


R.M.Adibhatla/R.J.Dempsey

Adibhatla-Phospholipases in Cerebral Ischemia, (429031), American Heart Assoc KY Affiliate, $15,000.

D.A.Blades/S.W.Scheff/V.Runge

*Effects of Basic Fiberoblast Growth Factor and Methylprednisolone on Experimental Spinal Cord Injury in the Rat, (429661), Kentucky Spinal Cord and Head Injury Trust, $97,456.

W.J.Clerici/M.R.Prasad

*Role of Reactive Oxygen Species in Ototoxicity, (429740), Natl Institute of Environmental Health Sciences, $94,988.

D.M.Cohen

*Mechanisms of Brain Injury and Its Systemic Sequelae, (433080), Natl Institute of Neurological Diseases & Stroke, $75,109 (adjustment).

R.J.Dempsey

Ornithine Decarboxylase & Ischemic Brain Edema, (427524), Neurological Communicative Disorders and Stroke, $216,422 (adjustment).

Pharmacokinetics and Safety of Tirilazad Mesylate at Doses of 6, 10, and 15 mg/kg/day in Patients with Subarachnoid Hemorrhage, (428667), Upjohn Company, $9,000 (adjustment).

B.Pan

Role of a 96 kDa Histone H2b Kinase and the Induction of Cell-Cycle Arrest, (429291), Natl Science Fdtn, $90,000.

Mechanism of Ras in Tumor Progression, (429807), Natl Cancer Institute, $159,315.

Oncogenic Ras and Cell Cycle Regulation, (428939), Council for Tobacco Research, $50,000.

R.A.Patchell

Surgery for Spinal Cord Compression Due to Cancer, (426516), Natl Cancer Institute, $112,791 (adjustment).

L.C.Pettigrew

*Patent Foramen Ovale in Cryptogenic Stroke (PICSS), (429874), Columbia Univ, $5,000.

L.C.Pettigrew/A.B.Young

*CERVENE Modification of Outcome in Patients with Acute Ischemic Stroke, (429615), Baker Norton Pharmaceuticals, $31,916.

*Warfarin Antiplatelet Recurrent Stroke Study, (429729), Columbia Univ, $80,650.

M.R.Prasad/S.Barron/P.J.Kraemer

*Chronic Ethanol in Traumatic Brain Injury, (429659), Kentucky Spinal Cord and Head Injury Trust, $94,671.

J.D.Ranseen/F.A.Schmitt/A.B.Young

*Evaluation of Personality Functioning Following Traumatic Head Injury Using the NEO-PI-R, (429660), Kentucky Spinal Cord and Head Injury Trust, $29,351.

S.W.Scheff

*Mechanisms of Brain Injury and Its Systemic Sequelae, (433077), Natl Institute of Neurological Diseases & Stroke, $143,518 (adjustment).

K.B.Seroogy/B.M.Davis/D.M.Yurek

*Neurotrophic Factor Analyses of Functinal Recovery, (429875), Neurological Communicative Disorders and Stroke, $179,120.

P.A.Sloan/M.B.Donnelly

*Equipping Medical Students to Manage Cancer Pain, (429735), National Hospice Fdtn, $2,000.

A.B.Young

Efficacy/Safety Study of 15 mg/kg/day Tirilazad Mesylate in North American Women with Subarachnoid Hemorrhage Protocol M/2700/0063, (429539), Upjohn Company, $24,000.

An Exploratory Study of Tirilazad Mesylate at (6,10,15 mg/kg/day) in Male Patients with Subarachnoid Hemorrhage Protocol M/2700/0062, (429540), Upjohn Company, $18,000.

ACAS-Asymptomatic Carotid Atherosclerosis Study, (429106), Wake Forest Univ, $21,070 (adjustment). Asymptomatic Carotid Artery Stenosis Study (ACASS), (433560), Wake Forest Univ, $8,055.

Mechanisms of Brain Injury and Its Systemic Sequelae, (433078), Natl Institute of Neurological Diseases & Stroke, $147,210 (adjustment).

Prevent: Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial, (426443), Wake Forest Univ, $140,675 (adjustment).

Multicenter, Randomized, Double-Blind, Parallel Group Trial, Comparing the Efficacy and Safety of Multiple Intravenous Bolus Injections of 5mg/kg of Selfotel with Placebo in Intubated Severe Closed Traumatic Brain Injury Patients, (429292), CIBA GEIGY Co, $15,693 (adjustment).

Mechanisms of Brain Injury and Its Systemic Sequelae, (433081), Natl Institute of Neurological Diseases & Stroke, $39,229 (adjustment).

Asymptomatic Carotid Artery Stenosis Study (ACASS), (429809), Wake Forest Univ, $39,532.

Mechanisms of Brain Injury and Its Systemic Sequelae, (428825), Natl Institute of Neurological Diseases & Stroke, $917,948 (adjustment).

ACAS-Asymptomatic Carotid Atherosclerosis Study, (433268), Wake Forest Univ, $21,070 (adjustment).

Head Injury Tirilazad Trial (HITT): A Multicenter Efficacy Study of Tirilazad Mesylate (U-74,006F) in Patients with Moderate and Severe Head Injury, (426699), Upjohn Company, $11,870 (adjustment).

A.B.Young/M.Kindy

*Mechanisms of Brain Injury and Its Systemic Sequelae, (433079), Natl Institute of Neurological Diseases & Stroke, $133,101 (adjustment).

*Mechanisms of Brain Injury and Its Systemic Sequelae, (433076), Natl Institute of Neurological Diseases & Stroke, $127,926 (adjustment).

A.B.Young/L.C.Pettigrew

North American Cooperative Study of Synptomatic Carotid Endarterectomy Agreement, (426629), John P Robarts Research Institute, $9,222 (adjustment).

D.M.Yurek

Factors Enhancing and Impairing Dopamine Grafts, (426813), Neurological Communicative Disorders and Stroke, $89,997 (adjustment).


Return to College of Medicine Departmental Listing

Return to Medical Center College Listing

Return to Top


Questions:

For questions regarding listings, contact Ms. Deborah Davis, director of the Office of Sponsored Projects Administration, 214 Kinkead Hall, 0057, phone 257-8311. (ddavis@pop.uky.edu )

Last Updated: 6/30/03